# **Table of Contents**

# State/Territory Name: Arizona

## State Plan Amendment (SPA) #: 22-0004

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form/Summary Form
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-26-12 Baltimore, Maryland 21244-1850



June 24, 2022

Jami Snyder, Director Arizona Health Care Cost Containment System 801 East Jefferson Street Phoenix, AZ 85034

Re: Arizona State Plan Amendment (SPA) 22-0004

Dear Ms. Snyder:

The Centers for Medicare & Medicaid Services (CMS) reviewed the proposed Medicaid State Plan Amendment (SPA) submitted under transmittal number (TN) 22-0004. This amendment proposes to assure the state's coverage of COVID-19 treatment, as required by section 1905(a)(4)(F) of the Social Security Act (Act).

Pursuant to section 1135(b)(5) of the Act, for the period of the public health emergency, CMS is modifying the requirement at 42 C.F.R. §430.20 that the state submit SPAs related to the COVID-19 public health emergency by the final day of the quarter, to obtain a SPA effective date during the quarter, enabling SPAs submitted after the last day of the quarter to have an effective date in a previous quarter, but no earlier than the effective date of the public health emergency.

Please note that the establishment of or changes to any payment methodologies approved to take effect after the end of the Public Health Emergency (PHE) in this SPA must meet the public notice requirements of 42 CFR 447.205.

CMS conducted our review of your submittal according to statutory requirements in Title XIX of the Act and implementing regulations. This letter is to inform you that Arizona's Medicaid SPA Transmittal Number 22-0004 is approved effective March 11, 2021.

If you have any questions, please contact Brian Zolynas at 415-744-3601 or via email at Brian.Zolynas@cms.hhs.gov.

Sincerely,

Alissa Mooney DeBoy On Behalf of Anne Marie Costello, Deputy Director Center for Medicaid and CHIP Services

CENTERS FOR MEDICARE & MEDICAID SERVICES	OMB №. 0938-C 1. TRANSMITTAL NUMBER 2. STATE
TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	
TO: CENTER DIRECTOR CENTERS FOR MEDICAID & CHIP SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES	4. PROPOSED EFFECTIVE DATE March 11, 2021
5. FEDERAL STATUTE/REGULATION CITATION Section 1905(a)(4)(F) of the Social Security Act	<ul> <li>6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars)</li> <li>a. FFY <u>2021</u> \$ <u>0</u></li> <li>b. FFY: <u>2022</u> \$ <u>0</u></li> </ul>
7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT Attachment 7.7-C Page 1-3	8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable) NEW
9. SUBJECT OF AMENDMENT ttests to the state's coverage of COVID-19 Treatment at section 1	905(a)(4)(E) of the Social Security Act
10. GOVERNOR'S REVIEW (Check One)	
GOVERNOR'S REVIEW (Check One) GOVERNOR'S OFFICE REPORTED NO COMMENT COMMENTS OF GOVERNOR'S OFFICE ENCLOSED NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	OTHER, AS SPECIFIED:
11. SIGNATURE OF STATE AGENCY OFFICIAL	15. RETURN TO
DAES	Dana Flannery 801 E, Jefferson, MD#4200 Phoenix, AZ 85034
12. TYPED NAME Dana Flannery	
13. TITLE Assistant Director	
14. DATE SUBMITTED: April 7, 2022	
FOR CMS	
16. DATE RECEIVED April 7, 2022	17. DATE APPROVEDJune 24, 2022
PLAN APPROVED - O	
18. EFFECTIVE DATE OF APPROVED MATERIAL March 11, 2021	19. SIGNATURE OF APPROVING OFFICIAL
20. TYPED NAME OF APPROVING OFFICIAL Alissa Mooney DeBoy	21. TITLE OF APPROVING OFFICIAL on Behalf of Anne Marie Costello, Deputy Director, CMCS
22. REMARKS	

### COVID-19 Treatment at section 1905(a)(4)(F) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

#### Coverage for the Treatment and Prevention of COVID

\_X\_\_ The states assures coverage of COVID-19 treatment, including specialized equipment and therapies (including preventive therapies).

\_\_\_X\_ The state assures that such coverage:

- 1. Includes any non-pharmacological item or service described in section 1905(a) of the Act, that is medically necessary for treatment of COVID-19;
- Includes any drug or biological that is approved (or licensed) by the U.S. Food & Drug Administration (FDA) or authorized by the FDA under an Emergency Use Authorization (EUA) to treat or prevent COVID-19, consistent with the applicable authorizations;
- 3. Is provided without amount, duration or scope limitations that would otherwise apply when covered for purposes other than treatment or prevention of COVID-19;
- 4. Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
- 5. Is provided to the optional COVID-19 group, if applicable; and
- Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(I) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.

\_X\_\_ Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.

\_X\_\_The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration.

Additional Information (Optional):

### Coverage for a Condition that May Seriously Complicate the Treatment of COVID

\_X\_\_ The states assures coverage of treatment for a condition that may seriously complicate the treatment of COVID-19 during the period when a beneficiary is diagnosed with or is presumed to have COVID-19.

- \_X\_\_ The state assures that such coverage:
  - 1. Includes items and services, including drugs, that were covered by the state as of March 11, 2021;
  - 2. Is provided without amount, duration or scope limitations that would otherwise apply when covered for other purposes;
  - 3. Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
  - 4. Is provided to the optional COVID-19 group, if applicable; and
  - Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(I) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.

\_X\_\_ Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.

\_X\_\_The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration.

Additional Information (Optional):

#### <u>Reimbursement</u>

\_\_\_X\_\_ The state assures that it has established state plan rates for COVID-19 treatment, including specialized equipment and therapies (including preventive therapies).

List references to Medicaid state plan payment methodologies that describe the rates for COVID-19 treatment for each applicable Medicaid benefit:

- 4.19-A Inpatient benefit
- 4.19-B, page 1a: Outpatient benefit
- 4.19-B, page 5c: Other Types of Care
- 4.19-B, page 2-2(a): Methodology for outpatient drugs including specialty drugs
- 4.19-D: Long term care facility benefit
- Page 97, Section 7.4, Section E.4: Lump sum nursing facility supplemental payments to compensate providers for the costs of covered services to improve the member's experience of care, during the COVID-19 PHE

- 4.19-B, page 7-9: IHS/638 Facilities are paid at the All-Inclusive Rate
- 4.19-B, page 3a-5: FQHCs/RHCs are paid at the PPS Rate

\_\_\_\_\_ The state is establishing rates or fee schedule for COVID-19 treatment, including specialized equipment and therapies (including preventive therapies) pursuant to sections 1905(a)(4)(F) and 1902(a)(30)(A) of the Act.

\_\_\_\_\_ The state's rates or fee schedule is the same for all governmental and private providers.

\_\_\_\_\_ The below listed providers are paid differently from the above rate schedules and payment to these providers for COVID-19 vaccines and the administration of the vaccines are described under the benefit payment methodology applicable to the provider type:

Additional Information (Optional):

**PRA Disclosure Statement** Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.